Impact of Exenatide on Cardiovascular Exercise Performance in Type 2 Diabetes (Exenatide)

This study has been completed.
Sponsor:
Collaborators:
Amylin Pharmaceuticals, LLC.
Eli Lilly and Company
Information provided by (Responsible Party):
University of Colorado, Denver
ClinicalTrials.gov Identifier:
NCT01364584
First received: May 24, 2011
Last updated: July 20, 2016
Last verified: July 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: December 2014
  Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)